The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Ranibizumab (Lucentis), an antibody fragment developed from bevacizumab, is an FDA-approved treatment for neo-vascular age-related macular degeneration (AMD) (Brown et al , 2006; Rosenfeld et al , 2006).”
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response
Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. A., & Lemke, G. (2007) · Cell · doi:10.1016/j.cell.2007.10.034 · Cited by 1,055
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis
Lu, Q., Gore, M., Zhang, Q., Camenisch, T., Boast, S., Casagranda, F., Lai, C., Skinner, M. K., Klein, R., Matsushima, G. K., et al. (1999) · Nature · doi:10.1038/19554 · Cited by 514
Signalling through the insulin receptor
Whitehead, J. P., Clark, S. F., Ursø, B., & James, D. E. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00079-4 · Cited by 130
Cited by
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
The role of microenvironment in tumor angiogenesis
Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., He, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01709-5 · Cited by 761
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Graham, D. K., DeRyckere, D., Davies, K. D., & Earp, H. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3847 · Cited by 698
Guo, S.-C., Tao, S.-C., Yin, W.-J., Qi, X., Yuan, T., & Zhang, C.-Q. (2017) · Theranostics · doi:10.7150/thno.16803 · Cited by 513
TAM Receptor Signaling in Immune Homeostasis
Rothlin, C. V., Carrera-Silva, E. A., Bosurgi, L., & Ghosh, S. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112103 · Cited by 510
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N., Wood, C. G., Matin, S. F., et al. (2016) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 395
Giving AXL the axe: targeting AXL in human malignancy
Gay, C. M., Balaji, K., & Byers, L. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.428 · Cited by 334
Lopatina, T., Bruno, S., Tetta, C., Kalinina, N., Porta, M., & Camussi, G. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-26 · Cited by 309
Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation
Wettschureck, N., Strilic, B., & Offermanns, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00037.2018 · Cited by 286
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
Burstyn-Cohen, T., Lew, E. D., Través, P. G., Burrola, P. G., Hash, J. C., & Lemke, G. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.015 · Cited by 163
“The possibility that TAM receptors might act independently of; that is, without a requirement for, their proposed ligands has also been advanced (Ruan and Kazlauskas, 2012).”
Genome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Metadata
- Authors
- Ruan, G., & Kazlauskas, A.
- Venue
- The EMBO Journal
- Published
- 2012-02-10
- Volume
- 31
- Issue
- 7
- Pages
- 1692-1703
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W1876403508
- Cited by
- 223
- References
- 9
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.